Skip to main content
OpenTrials
Not Yet Recruiting

NCT Number: NCT04205877

The U.S. PDA Registry

The objective of this study is to demonstrate the continued safety and efficacy in a real-world setting of transcatheter device closure of the PDA in premature infants less than 2kg in weight at the time of device implant using the Amplatzer Piccolo Occluder device and other devices performed in the USA.

Not Yet Recruiting

Trial opening soon.

Get Notified

Key information

Age range

3 day–1 year

Sex eligibility

All sexes

Study type

Observational

Primary location

About this study

Based on the IMPACT registry, there are over 6000 transcatheter device closures of PDA that occurs in the United States annually. However, there are no comprehensive data collection tools for this procedure. The current databases do not include multiple data points, or follow-up data, or a section for specific adverse events to be documented. Moreover, until now, there has been no approved devices for PDA closure in children < 2kg. This clinical study is the first of its kind to collect data from all transcatheter device closure of PDA in children < 2kg performed in the USA.This study will be limited to children between 700 to 2000 grams who are the most vulnerable population undergoing this procedure. This will allow us to understand the real world experience (efficacy and safety) of using the Amplatzer Piccolo Occluder and other devices in an extremely vulnerable, yet highly underserved population. The study will allow for standardization of this procedure throughout the country for the small children (<2 kg) with a PDA. This is a multi-center, single arm, observational data collection study. This will be a large population study to help analyze outcomes in subjects <2 kg. The trial has two primary endpoints for safety and effectiveness without formal hypothesis. The safety and effectiveness results will be compared with data reported in the ADO II AS IDE and Continued Access Protocol studies.

Who can participate

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Diagnosis of PDA.
  • Clinical indication for transcatheter PDA closure (discretion of the physician).
  • Weight <2 kg at the time of device implant.

Exclusion criteria

  • Weight <700 gm or greater than or equal to 2 kg at the time of device implant.
  • Age < 3 days at the time of device implant.
  • Pre-existing coarctation of the aorta.
  • Pre-existing left pulmonary artery stenosis.
  • Cardiac output that is dependent on right to left shunt through the PDA due to pulmonary hypertension.
  • Intracardiac thrombus that interferes with device implant.
  • Active infection requiring treatment at the time of impant.

Treatment and study plan

Transcatheter PDA Closure

Device

Device utilized for closure of PDA, study is to help assure continued safety and effectiveness of FDA approved Amplatzer Piccolo Occluder device as well as other devices used off label for PDA closure in premature infants less than 2 kg at the time of device implant.

Primary outcomes

  1. Vascular Access Complications (Safety)

    Time frame: 6 months

    Access vessel complications include femoral arterial or femoral/jugular venous complications noted during the procedure, immediately after the procedure or delayed (>24 hours). They range from bleeding from access sites, arterial or venous thrombosis with or without the need for treatment to loss of limb secondary to arterial occlusion.

  2. Valvular Injury (Safety)

    Time frame: 6 months

    Valvular injury includes damage to the tricuspid valve or other cardiac valve resulting in immediate post-procedural valvular dysfunction.

  3. Device Embolization (Safety)

    Time frame: 6 months

    Device embolization includes malposition of the device either during or after the procedure or delayed (>24 hours). The outcome of device embolization ranges from observation, transcatheter retrieval at time of procedure or at a separate time, surgical retrieval, other end organ damage, to mortality.

  4. Pulmonary or Aortic Vessel Stenosis (Safety)

    Time frame: 6 months

    Adjacent vessel stenosis includes a narrowing of the aorta or the left pulmonary artery directly as a consequence of device implantation for PDA closure. Vessel stenosis could happen either during or after the procedure or delayed (>24 hours). The outcome of vessel stenosis ranges from no intervention needed to repeated transcatheter and surgical therapies.

  5. Rate of Effective PDA Closure (Effectiveness)

    Time frame: 6 months

    The effectiveness endpoint is the rate of effective closure of the PDA using a transcatheter device within six months post procedure. If more than one attempt is required, or multiple devices are required during the same procedure, it is still considered effective if there is Grade 0 or Grade 1 shunt, as defined below, at follow-up by transthoracic echocardiography or if a second procedure is not required following the initial attempt. If there is device embolization, adjacent vessel stenosis that required retrieval of the device and replacement during the same procedure with less than Grade 1 shunt during follow-up, it is still considered effective. Conversely, if an AE is noted after the procedure that requires a second procedure for treatment that results in greater than Grade 1 shunt, then the procedure is considered not effective, even if the initial attempt was effective. See protocol for PDA shunt definitions.

Secondary outcomes

  1. Significant obstruction of the left pulmonary artery

    Time frame: 6 months

    Significant obstruction of the left pulmonary artery is defined as less than 30% flow to the left lung by lung perfusion scan or a peak instantaneous gradient in left pulmonary artery

    ≥35 mmHg by echocardiogram if lung perfusion scan is not available or as determined by the interventional cardiologist based on angiographic appearance.

  2. Significant obstruction of the aorta

    Time frame: 6 months

    Significant obstruction of the aorta is defined as a gradient of ≥20 mmHg in the aortic isthmus by invasive aortic catheterization or a mean gradient ≥20 mmHg in the aortic isthmus by echocardiogram if invasive aortic catheterization is not available.

Study contacts

Contact information is provided by the study sponsor or research team.

Jorden Cunningham, BSN

CONTACT

[email protected]

901-287-7457

Shyam K Sathanandam, MD

CONTACT

[email protected]

901-287-6380

Sponsors and collaborators

Lead sponsor

Le Bonheur Children's Hospital

Other

Collaborators

  • Abbott

Registry information

Official study title

The United States Patent Ductus Arteriosus Registry

Important dates

Study start
2020
Primary completion
2030
Study completion
2031
First posted
Dec 20, 2019
Registry last updated
Dec 20, 2019

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.